XASXBDX
Market cap22mUSD
Jan 08, Last price
0.10AUD
1D
0.00%
1Q
-28.15%
IPO
56.45%
Name
BCAL Diagnostics Ltd
Chart & Performance
P/E
—
P/S
11.46
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.74%
Rev. gr., 5y
64.37%
Revenues
3m
+8.60%
Net income
-6m
L+26.44%
CFO
-5m
L-25.21%
Profile
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||
Revenues | 3,098 8.60% | 2,853 296.94% | 719 161.09% | ||||
Cost of revenue | 6,242 | 5,893 | 3,145 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (3,144) | (3,040) | (2,426) | ||||
NOPBT Margin | |||||||
Operating Taxes | (3,047) | (46) | (19) | ||||
Tax Rate | |||||||
NOPAT | (97) | (2,994) | (2,408) | ||||
Net income | (6,400) 26.44% | (5,062) 49.51% | (3,385) 122.00% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 9,409 | 50 | 9,409 | ||||
BB yield | -30.57% | -0.34% | |||||
| Debt | |||||||
Debt current | 442 | 165 | |||||
Long-term debt | 1,964 | 1,958 | |||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | (4,067) | (1,051) | (9,571) | ||||
| Cash flow | |||||||
Cash from operating activities | (4,523) | (6,048) | (3,219) | ||||
CAPEX | (1,151) | (362) | (4,026) | ||||
Cash from investing activities | (1,151) | 3,638 | (4,026) | ||||
Cash from financing activities | 8,973 | 13 | 9,409 | ||||
FCF | 2,390 | (8,985) | (2,344) | ||||
| Balance | |||||||
Cash | 6,473 | 3,174 | 9,571 | ||||
Long term investments | |||||||
Excess cash | 6,318 | 3,031 | 9,535 | ||||
Stockholders' equity | 8,588 | 5,214 | 9,640 | ||||
Invested Capital | 3,794 | 3,244 | 104 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 246,225 | 210,903 | 204,286 | ||||
Price | 0.13 78.57% | 0.07 | |||||
Market cap | 30,778 108.48% | 14,763 | |||||
EV | 26,712 | 13,712 | |||||
EBITDA | (2,564) | (2,927) | (2,406) | ||||
EV/EBITDA | |||||||
Interest | 100 | 16 | |||||
Interest/NOPBT | |||||||